Cigna (CI)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
$288.90-0.40%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-14
Research Workspace
Put CI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
No standing thesis yet — not enough to read.
View ThesisRevenue growth is slowing — up about 8% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCigna Group (CI) must continue to grow its Evernorth Health Services to justify its price. Revenue grew 7% year over year, and the last quarter beat expectations. CI trades at 8.9× P/E versus a peer median of 22×, indicating the price reflects less growth than forecast. If CI reverses and cuts guidance after recently raising it, that could harm credibility. Peer multiples imply a price about 28% above where it trades. This read is provisional.
Trailing returns as of 2026-09-15. CI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 25 analysts currently covering CI (as of Sep 2026).
Based on 12 Wall Street analysts offering 12-month price targets for CI in the last 4 months.
Continue this research
Compare CI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put CI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Grow Evernorth Health Services adjusted income
Concerns over PBM transition risk may hinder Evernorth growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $288.90
The last 12 months of price, then the range of analyst 12-month targets from today’s $288.90.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Grow Evernorth Health Services adjusted income
New platform supports growth in Evernorth Health Services income.
Advances: Grow Evernorth Health Services adjusted income
Evernorth's SEC clearance supports growth in health services.
Advances: Grow Evernorth Health Services adjusted income
Evernorth's SEC clearance supports growth objectives.
Advances: Grow Evernorth Health Services adjusted income
Evernorth's revised terms enhance growth potential.
Advances: Reach adjusted revenue goal
Raised outlook supports revenue growth expectations.
Downgrade indicates potential earnings pressure affecting growth outlook.
Downgrade indicates potential earnings challenges ahead.
